Although it is known that rubella-immune individuals have T cells that proliferate in vitro in response to rubella virus (RV), the determinants that evoke this response have not been identified. This study utilized recombinant proteins that express overlapping sequences of the RV structural open reading frame to identify domains of the structural proteins that contain cell-mediated immunodominant sequences. Lysates enriched with RV fusion proteins (RecA-RV-LacZ) were prepared from Escherichia coli transformed with plasmids which contained specific RV eDNA inserts. Approximately 62 % of RV-immune individuals gave RV-specific responses to one or more of the RV fusion proteins. Over 10 %o of immune individuals recognized the capsid sequence C1-Ceg. Lymphoproliferation data from studies using six overlapping synthetic peptides representing this sequence suggested that as much as 70 % of the immune population may recognize this domain. An E1 sequence, E1202-E1283, was recognized by 15 % of the RV-immune individuals with the fusion proteins. Five synthetic peptides representing this sequence had an overall response rate of 50 %. The sequence C~4-C97 failed to evoke any RV-specific responses with the fusion proteins and synthetic peptides representing this sequence were used to verify that the RV fusion proteins and the criteria used to identify RV-specific responses were adequate. These peptides gave a response rate of only 6%. In general, significant responses to specific fusion proteins correlated with high responses (stimulation index ~> 4.0) to representative synthetic peptides. This study suggests that the recombinant proteins were beneficial in identifying cell-mediated immunodominant domains of the RV structural proteins which could be further characterized with synthetic peptides.
Introduction
Rubella is typically a mild childhood disease but complications are common when adults are infected. The most devastating effects of rubella occur when a foetus is infected in utero. Surviving infants with the congenital rubella syndrome (CRS) may show continued viral replication and organ damage many months postpartum. Virus replication persists even though the infected foetus generates IgM and acquires IgG transplaeentally, both capable of neutralizing the virus in vitro (Cooper & Krugman, 1966; Cooper et al., 1969) . The mononuclear cells of CRS children show abnormal responses to mitogens (Olson et al., 1968) and impaired in vitro lymphokine production (Buimovici-Klein et al., 1979; Buimovici-Klein & Cooper, 1985) . These observations suggest that altered cell-mediated immunity (CMI) may limit virus clearance in these children. Late onset complications of CRS include juvenile onset diabetes mellitus (Norris et al., 1987; Shaver et al., 1985) and progressive rubella panencephalitis (Wolinsky, 1990) , the pathology of both resulting from immune-mediated destruction of selected tissues. Rubella infection of adults, whether natural or as a result of immunization, is often complicated by arthralgia, especially in postpubescent women. Although symptoms usually resolve within a few weeks, some individuals experience joint pains for years (Ford et al., 1992) . Furthermore, RV has been isolated from synovial fluids of symptomatic joints of individuals with apparently adequate humoral responses (Chantler et al., 1982 (Chantler et al., , 1985 .
Unfortunately, the role that CMI plays in the recovery from rubella virus (RV) infection and in immunopathological syndromes associated with RV is unknown. CMI has been shown to play a significant role in the recovery from some viral infections and may be an essential mechanism for eliminating non-cytopathic viruses such as R¥. Furthermore, altered CMI responses may be partially responsible for the complications of viral infections. Mapping T cell epitopes of RV is essential to understanding the interaction of T cells with RV antigens and antigen-presenting cells and should enhance our understanding of the immune mechanisms that provide protective immunity to RV. Such data from normal individuals would make it possible to determine whether regions processed and presented to T cells differ 0001-1235 © 1993 SGM Two of the domains that were identified with the RV fusion proteins were selected for more detailed characterization with synthetic peptides. Synthetic peptides representing these domains verified the specificity of the responses seen with the RV recombinant proteins.
Methods
Study population. Forty-five healthy adults, 25 females and 20 males, of diverse major histocompatibility complex (MHC) and ethnic backgrounds were used in this study. Their ages ranged from 22 to 49 years and most were employees or students at the Texas Medical Center. Donors were given a questionnaire regarding their history of exposure to RV. Of the individuals who responded, about 20 % recalled having natural rubella infection, 70 % recalled having been vaccinated and 10 % knew of no exposure to RV. However, the reliability of this information is questionable since many cases of natural rubella infection are subclinical and many individuals were quite uncertain about past exposure to RV. It was clear from the questionnaires and evaluation of humoral and cellular immune responses to RV that most individuals had remote immunity, although several individuals had recieved a recent MMR vaccination because of an outbreak of measles (rubeola).
RV fusion proteins.
A family of plasmids containing RV cDNA fragments was generated which contain overlapping sequences representing the RV structural ORF. Details of the construction and characterization of most of the plasmids used in this study have been described previously (Wolinsky et al., 1991) . In brief, specific Therien strain RV cDNA fragments were obtained from RV cDNA inserts contained in pUC8 (Frey et al., 1986; Frey & Marr, 1988) by the use of restriction enzymes, digestion with blunt end nucleuses or through polymerase chain reaction (PCR) amplification strategies. The RV cDNA fragments were then inserted into one of three pGE374-derived expression vectors. These expression vectors contain a recA promoter followed by a sequence encoding 35 to 40 amino acids of RecA, a short sequence containing two to four unique restriction sites, and a sequence encoding 1007 amino acids of fl-galactosidase (LacZ) (Weinstock, 1984) . In pGE374, recA and lacZ were out of frame, but insertion of the appropriate RV cDNA fragment into a restriction site located between these two sequences re-established the correct reading frame allowing expression of LacZ. In pGE372, recA and lacZ were in frame and insertion of an RV cDNA fragment disrupted the reading frame of lacZ resulting in only a limited number of residues being expressed before a stop codon was reached. A modified version of pGE372, pGE372DBI, was generated by altering the sequence between the NeoI and BamHI restriction sites so that it contained two additional restriction sites useful for insertion of PCR-amplified cDNA fragments. Consequently, these ptasmids expressed a fusion protein containing 35 to 40 amino acids of RecA, an RV sequence and either a few random amino acids encoded from the lacZ gene out of frame, or 1007 amino acids of LacZ (Fig. 1) . Two previously undescribed constructs were also used. The plasmid pARV16-07 expresses a fusion protein containing 35 residues of RecA, the entire capsid sequence, the first 13 residues of E2, and a 50 residue nonsense sequence from LacZ. The plasmid p9/SpII, derived from p9, expresses 43 residues of RecA, E1 residues 162 to 296, and 93 residues from the LacZ gene. The RV fusion proteins are designated by the name of their plasmid (Wolinsky et al., 1991) .
Escherichia coli strain MC 1061 was transformed with these plasmids and grown in LB broth. When the cell density reached about 3 x 108 cells/ml, mitomycin C was added to the culture at 1 ~g/ml to induce over-expression of the fusion protein. On the following day, the cells were washed, resuspended in 100mM-Tris-HC1/10mM-EDTA, pH 7.4, and sonicated using a micro-ultrasonic cell disrupter (Kontes). After centrifugation (Model TJ-6, Beckman Instruments) at 1800g for 20 rain, the supernatant was recovered and the protein concentration was determined. Expression of the fusion protein was verified by ELISA and Western blotting using rabbit polyclonal antiRecA (provided by Dr Julian Leibowitz), monoclonal anti-LacZ (Promega), and monoclonal antibodies (MAbs) known to react with specific linear RV sequences (Wolinsky et al., 1991) .
SDSPAGE and hnmunoblotting. Using standard PAGE techniques (Laemmli, 1970) , the RV fusion protein lysates were analysed on 6, 8 or 10% resolving gels using a discontinuous buffer system. The proteins were either stained with Coomassie blue or electrophoretically transferred to nitrocellulose for immunoblotting. The basic immunoblotting protocol based on the method of Towbin et al. (1979) has been described previously in detail (Wolinsky et al., 1991) . In brief, the nitrocellulose was incubated with an RV-specific MAb monoclonal anti-LacZ (Promega), or polyclonal rabbit anti-RecA serum (Leibowitz et al., 1988) . The secondary antibody was an alkaline phophataseconjugated anti-mouse or anti-rabbit lgG (Promega). Nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate were used to develop the insoluble product.
Synthetic peptides. Synthetic peptides were initially designed to identify linear B cell epitopes within the RV structural proteins, as reported previously in detail (Wolinsky et al., 1991) . Additional peptides were made to alter predicted T cell recognition motifs (Rothbard & Taylor, 1988) . In general, peptides were generated on an automated peptide synthesizer using Merrifield et al. (I 982) solid phase methodology based on standard tertbutyloxycarbonyl amino acid protocols and their expected composition was confirmed by fast atom bombardment mass spectrometry (Moore et aL, 1992) .
ELISA for determining R V antibody titres.
To determine whether the individuals in the study population were seropositive for RV antibodies, an ELISA using sucrose gradient-purified rubella virions [25 haemagglutination units (HAU)/ml] as the target was used (Nath et al., 1989) . On each of the ELISA plates a standard serum was used at multiple dilutions to generate a third order regression curve. The standard serum had 25000 RV antibody units/ml (1 unit is defined as the limit dilution of standard serum that generated a final absorbance > 3 standard deviations over background). Each individual's serum was tested at three dilutions (1:200 to 1:2000) such that at least two dilutions fell on the curve. removed. The PBMCs were washed and the platelets were removed by centrifugation at 150 g for 10 min. The PBMCs were then resuspended in RPMI 1640 containing 10% heat-inactivated pooled human AB serum (Nabi), 10m~-HEPES buffer, 100units/ml penicillin and 100 pg/ml streptomycin, and plated into 96-well round-bottomed trays at 10 ~ cells per well. In quadruplicate, 50 ~tg/ml of RV fusion protein lysate, 25 HAU/ml u.v.-inactivated RV, 20 lag/ml synthetic peptide, or medium only was added to each well with a final volume of 0.2 ml per well. After a 5 day incubation at 37 °C, 1 I~Ci of [~H]thymidine in 50 ~tl medium was added to each well. The PBMCs were harvested onto glass fibre filter discs after 18 to 20 h using a semi-automated cell harvester (Cambridge Technology) and liquid scintillation counting was used to determine the amount of [aH]thymidine incorporated. The stimulation index (SI) for the lymphoproliferative response to each protein lysate and synthetic peptide was determined. SI was defined as the ratio of the c.p.m, of the cells cultured with the antigen to the c.p.m, of the cells cultured in medium only.
R e s u l t s
Immune status of the study population to R V To determine whether the individuals in our study p o p u l a t i o n were seropositive to RV, an E L I S A using RV virions as the target was utilized. A reciprocal a n t i b o d y titre/> 12500 u n i t s / m l was considered seropositive. This value was determined previously by standardizing this assay with the conventional h a e m a g g l u t i n a t i o n inhibition assay (J. S. Wolinsky, u n p u b l i s h e d data). Using this value, 42/45 (93 %) of the n o r m a l d o n o r p o p u l a t i o n used in the present study were seropositive for RV antibodies, with a m e a n titre of 48 800 u n i t s / m l . A n SI to RV in the lymphocyte proliferation assay of ~> 2.5 was considered significant (Buimovici-Klein et al., 1976) . I n our population, 42/45 (93 %) showed a positive lymphoproliferative response to RV with a m e a n SI of 15"5. All 42 seropositive individuals also showed positive proliferative responses and were considered to be RVimmune. The three individuals who had a n t i b o d y titres < 12500 u n i t s / m l were those who had SI values < 2.5; these individuals were considered to be susceptible to RV infection. 
Identification of potential cell-mediated immunodominant domains using R V fusion proteins
These assays were carried out using lysates of bacterial cultures expressing the fusion proteins (Fig. 1) . Expression of the RV fusion proteins was verified by PAGE and immunoblotting (Fig. 2) . These experiments contained two controls. First, the amount of [3H]thymidine incorporation due to spontaneous proliferation was controlled by exposing PBMCs to medium only. This value served as the denominator in the SI. Second, the amount of proliferation due to the RecA and LacZ portions of the fusion proteins, as well as any E. coli proteins in the crude lysates, was controlled. For each individual, PBMCs were stimulated with a lysate of E. coli transformed with the plasmid, pGE372, which expresses a fusion protein containing the RecA and Lac Z sequences. For a response to a given RV fusion protein to be considered positive and specific for the RV sequence, the response to the RV fusion protein lysate had to be /> 150% of the SI of the control (pGE372) lysate. An increase of 50 % more than the control lysate was at least 2 standard deviations over background. Table 1 shows representative data of one individual's responses to several of the RV fusion protein lysates as an example of how the data were evaluated. Table 2 summarizes the responses of the study population to the RV fusion protein lysates using these criteria. Individuals were considered RV-immune if they had RV antibody titres >~ 12500 units and an RV SI >~ 2.5. None of the RV-susceptible individuals showed RVspecific responses to any of RV fusion protein lysates. Therefore, the positive responses to these lysates were limited to individuals who were RV-immune. A majority of the RV-immune individuals, 26/42 (62%), gave a significant response to at least one of the RV fusion protein lysates. This suggested that the RV fusion proteins and the criteria established to determine RVspecific responses were sensitive enough to detect RVspecific lymphoproliferative responses in most of the RV-immune individuals. Synthetic peptides representing selected RV sequences were used to verify and characterize potential T cell epitopes identified with the RV fusion proteins.
Confirmation of two RV T cell epitopes with synthetic peptides
Three regions were chosen for further characterization with synthetic peptides: A, amino acids 1 to 29 of the capsid, C1-C~9; B, amino acids 202 to 283 of El, E1202-E1283; and C, amino acids 64 to 97 of the capsid, C64-C9v. These regions were chosen for further characterization for several reasons. Two of the three regions (A and B) had been shown to contain sequences capable of stimulating T cells in at least 10 % of the RV-immune population by the RV fusion proteins, but the third region (C) showed no significant responses with the RV fusion proteins (Table 2 ). The two regions (A and B) that appeared to contain T cell epitopes had sequences consistent with T cell recognition motifs described by Rothbard & Taylor (1988) , but the third region did not have such a motif (Table 3 ). All three regions were shown previously to contain B cell epitopes (Wolinsky et aI., 1991) and initial synthetic peptides were available to determine whether these sequences contained T cell epitopes. By characterizing these three regions, the ability of the RV fusion proteins to direct our attention to regions that contain T cell epitopes was determined. Additionally, potential contiguous B cell and T cell epitopes that might be useful in designing synthetic vaccines were investigated.
At least 10 % of the study population appeared to recognize region A (C1-C29) (Table 2, pRN), a relatively short amino acid sequence within the amino-terminal portion of several of the RV fusion proteins (Fig. 1) . This is illustrated by the response pattern to the RV fusion proteins of a representative individual in Table 4 ; there were positive responses to pRN, pARV1607 and pN5. These fusion proteins share amino acids 9 to 29 of the capsid, indicating that this sequence contains a T cell epitope. This subject showed significant proliferation in response to synthetic peptides SP-2 (C14-C20 and SP-8 (C9-C29), but not SP-1 (C1-Cxs). This region of the capsid contains two 4 amino acid sequences, KALE and RALR, which are consistent with predicted T cell recognition motifs (Rothbard & Taylor, 1988) (Table 3) . The preliminary data suggested that SP-2 and SP-8, which both contain the two predicted T cell recognition motifs, stimulated significant responses in a large cohort of donors (Table 5) . Three additional synthetic peptides were then made to improve the characterization of this region. SP-14 (C9-C2z) had a truncated RALR sequence, SP-16 had two additional amino acids at the amino terminus of SP-2 to define further the amino terminus of a murine B cell epitope in this region (Wolinsky et al., 1991) , and SP-19 had a KALE sequence disrupted by a single conservative amino acid substitution of alanine for serine at C15 (Table 3) .
Overall, 30/42 (71%) of the RV-immune population had an SI ~> 2"0 to one or more peptides representing C1-C29, and 8/42 (19 %) had an SI >/4.0 to at least one of these six peptides (Table 5) . Analysis of the responses to these synthetic peptides showed that 5/8 (63 %) of the individuals who had an SI ~> 4"0 to at least one of these six synthetic peptides showed a significant response to one or more of the RV fusion proteins that contained the C1-C29 region (i.e. pRN, pARV16-07 and pN5). The three high peptide responders (SI >/4.0) who did not give significant responses to the RV fusion proteins had SI values to the synthetic peptides ~< 5.0. However, 4/5 (80 %) of the high peptide responders who recognized this region with both the RV fusion proteins and synthetic peptides had SI values to the synthetic peptides well above 5.0. This suggests that the RV fusion proteins were more successful at identifying vigorous responders. The synthetic peptides were better for recognizing individuals who had modest responses (SI ~> 2.0 < 4-0) to this region, 22/42 (52 %). Only 6/22 (27 %) of the modest synthetic peptide responders to this region gave significant responses to at least one of the RV fusion proteins containing this sequence.
A review of individuals who were tested with all six synthetic peptides indicated that a response to SP-1 was usually independent of a response to any of the other synthetic peptides. Since SP-14, which had a low response rate, contained the predicted T cell motif KALE sequence also present in SP-1, the T cell epitope in SP-1 must be dependent on sequences other than KALE. The responses to SP-2, SP-8, SP-16 and SP-19 appeared to be correlated. Alteration of the KALE sequence in SP-19 did not change the response pattern, but disruption of the RALR sequence in SP-14 resulted in a peptide that failed to stimulate proliferation of lymphocytes from individuals who responded well to SP-2, SP-8, SP-16 and SP-19. This suggests that this region may actually contain two independent epitopes: one in C1-Cls and one in C14-C29.
At least 18 % of this RV-immune population recognized region B (El 202-E 1283), based on the response rate to pARV02-01, the RV fusion protein containing this exact RV sequence (Table 2) . Five synthetic peptides were generated representing this region (Table 3 ). In the RVimmune population, 7/42 (17 %) had an SI >~ 4.0 to one of these synthetic peptides and 14/42 (33%) had an SI >~ 2.0 ~< 4-0 (Table 6 ). Of the seven high responders, four (57 %) gave a significant response to one or more of the RV fusion proteins representing this region. Of the 14 individuals who showed modest responses to one of these synthetic peptides, only five (36%) gave a significant response to pARV1001, p9, p9/SplI or pARV0201. Although all five synthetic peptides representing the region E1202-E12s 3 had predicted T cell recognition motifs, their ability to elicit T cell proliferation in vitro varied significantly. SP-15, which can bind MAbs capable of neutralizing the virus (J. S. Wolinsky, unpublished data), had an extremely low response rate, 3 %. SP-11 and SP-12, which overlap significantly with SP-15, had higher response rates (19 % and 13 %, respectively). SP-7, which contained three predicted T cell motifs, had the highest response rate, 38 %. Overall, 21/42 (50 %) of the RV-immune individuals had an SI/> 2'0 to one or more of the peptides representing E120~-E12s 3.
A third sequence, region C (C~4-Ca7), was chosen for analysis as a control. Since this region did not give any significant responses with the RV fusion protein, pBstUI (Table 2) , the ability of the RV fusion proteins and the criteria for determining RV-specific responses to discriminate accurately between regions with and without T cell epitopes were verified. Two synthetic peptides were made. SP-9 contained C78-C97 and SP-10 contained the entire RV sequence of pBstUI, C64-C97 (Table 3) . Only 1/33 of the study population had an SI ~> 2.0 < 4.0 to SP-9 and there were no SI values >~ 4"0 (Table 7) . For SP-10, this same individual had an SI >/2.0 < 4.0 and an additional individual had an SI ~> 4.0. This extremely low response rate with these synthetic peptides correlates with the lack of responses seen with the RV fusion protein pBstUI.
Discussion
Previous studies have demonstrated that lymphocytes of RV-immune individuals proliferate in vitro in the presence of RV (Buimovici-Klein et al., 1976; BuimoviciKlein & Cooper, 1985) . Considerable progress has been made in the molecular characterization of RV, and the availability of the gene sequence of this positive-strand RNA virus has opened the way for a more detailed analysis of the targets for humoral and cellular immunity. However, as yet only one study has examined the capsid protein as a target for T cells (Ou et al., 1992) and the role of the glycoproteins E1 and E2 in contributing to CMI has not been addressed. This study investigated the use of recombinant proteins expressing overlapping sequences of the structural ORF of RV to identify domains of the RV structural proteins that contain T cell epitopes.
We first separated our pool of normal, healthy donors into those with immunity to RV as defined by conventional measures of humoral and cellular immunity to whole virus targets, and those susceptible to infection. As anticipated for the age of the study population and location of the institution, approximately 90 % of these individuals were RV-immune. We had assumed that purified fusion proteins would be necessary to test for RV-specific proliferation. However, lysates enriched with the RV fusion proteins by mitomycin-induced overexpression and through the removal of non-soluble proteins by centrifugation proved capable of evoking significant and specific proliferation in vitro by lymphocytes of RV-immune individuals. Consequently, criteria were established to identify responses specific for RV sequences using these protein preparations. With these criteria, 26/42 (62%) of the RV-immune individuals gave a significant response to one or more of the RV fusion proteins.
There could be several reasons why individuals who had lymphoproliferative responses to RV virions did not show significant proliferation in response to any of the R¥ fusion proteins. First, the lysates used and the criteria established to identify RV-specific responses may not have been sensitive enough to recognize modest responses. The data obtained with synthetic peptides suggest that this occurred. For example, 4/5 (80 %) of the high synthetic peptide responders who recognized C1-C2~ with both the RV fusion proteins and synthetic peptides had SI values to the peptides well above 5, whereas only 6/22 (27 %) of the modest synthetic peptide responders to this region had a significant response to one or more RV fusion proteins containing this sequence. Second, although most individuals were screened with most of the RV fusion proteins, many individuals were not screened with all of the lysates. This may have resulted in an overall response rate lower than it might have been had all 45 individuals been tested with all of the RV fusion proteins. If only the individuals who were screened with all of the lysates are considered, the overall response rate was 73 %. Finally, two short sequences within E1 were not represented in any of the RV fusion proteins, and these domains could be capable of eliciting lymphoproliferative responses. Regardless, the panel of overlapping RV fusion proteins enabled identification of several potential immunodominant T cell epitopes. It is those determinants which appear to be dominant in a heterologous donor population that could prove most useful in designing new synthetic vaccines.
Although the RV fusion proteins may not detect all modest RV lymphoproliferative responses, differences in antigen processing and presentation of the RV fusion proteins and synthetic peptides may account partially for the significantly higher response rates with the synthetic peptides. Exogenous proteins, such as the R¥ fusion proteins, are generally digested by enzymes in lysosomes of antigen-presenting cells and the resulting peptides of the appropriate affinity bind to MHC class II molecules and are presented on the surface of these cells. Since peptides bound to MHC class II molecules are recognized by CD4 + helper T cells, proliferation to the RV fusion proteins should be limited to CD4 ÷ T cells. Fluorescence cell sorting analysis of our cultures with CD4-and CD8-specific MAbs shows that this is true (unpublished data). In contrast, synthetic peptides may not need to be processed and subsequently may bind directly to either MHC class I or II molecules (Townsend et al., 1986) . Therefore, CD4 ÷ T cells, and CD8 + T cells that recognize peptides bound to MHC class I molecules, may proliferate in the presence of the synthetic peptides. Although these studies do not address whether CD8 + T cells play a role in RV immunity, the realistic possibility that they are active in viral clearance and immunopathological consequences associated with RV should not be overlooked.
The RV fusion proteins may also be useful in identifying differences in RV sequences recognized by lymphocytes of patients with CRS, RV-associated arthritis or putative immune-mediated diseases associated with RV. Even when a full battery of immunodominant T cell epitopes are reduced to the peptide level for the normal population, screening patient populations with these peptides may not reveal differences. This is because sequences not normally recognized might elicit lymphoproliferative responses only in those donors with RVassociated diseases. Since this strategy using exogenous recombinant proteins selects for CD4 + T cells, viral vectors expressing each RV structural protein may also be useful for identifying differences in responses by CD8 + T cells (Lovett et al., 1992) in certain populations.
The intention of this study was to identify domains within the RV structural proteins that contain T cell epitopes by using recombinant proteins. Of the three domains selected for characterization with synthetic peptides, the two identified by a proliferative response to their representative RV fusion proteins were verified to contain T cell epitopes. These three domains are currently being studied extensively, including MHC restrictions, phenotypic characterization and precursor frequency in a larger donor population. Since this strategy utilizing recombinant proteins and synthetic peptides was useful in identifying both linear B and T cell epitopes for RV, it may be useful for identifying contiguous B and T cell determinants of other pathogenic agents. This study suggests that overlapping B cell and T cell epitopes may not be unusual. Additional potential immunodominant domains have been identified with these and other RV fusion proteins, such as E1297-E13~ 2. This domain contains four predicted T cell recognition motifs and is the only sequence unique to p9 which had the highest response rate (41%) of any of the RV fusion proteins. T cell determinants in this domain and additional domains which are not known to contain B cell epitopes are currently being defined.
